• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Sarepta Therapeutics, Inc. (SRPT)

    -NasdaqGS
    13.21 Down 0.59(4.28%) Dec 19, 4:00PM EST
    |After Hours : 13.55 Up 0.34 (2.57%) Dec 19, 7:48PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Sarepta Therapeutics, Inc.
    215 First Street
    Suite 415
    Cambridge, MA 02142
    United States - Map
    Phone: 857-242-3700
    Website: http://www.sareptatherapeutics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:146

    Business Summary 

    Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sarepta Therapeutics, Inc.

    Corporate Governance 
    Sarepta Therapeutics, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Christopher Nishan Garabedian , 47
    Chief Exec. Officer, Pres and Director
    1.12M0.00
    Mr. Sandesh Mahatme LL.M., 49
    Chief Financial Officer, Chief Accounting Officer and Sr. VP
    749.00K0.00
    Dr. Jayant Aphale Ph.D., MBA, 54
    Sr. VP of Technical Operations
    511.00K0.00
    Mr. David Tyronne Howton , 42
    Sr. VP, Gen. Counsel and Corp. Sec.
    554.00K0.00
    Dr. Edward M. Kaye M.D., Ph.D., 65
    Chief Medical Officer and Sr. VP
    562.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders